breast cancer
Conditions
Interventions
experimental group :vinorelbine soft capsule combined with capecitabine
Sponsors
Hubei Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged =18 years and =70 years; 2. Breast cancer patients confirmed by pathology and conforming to the clinical diagnostic criteria for advanced breast cancer; At least one measurable target lesion (according to RECIST V1.1 standard); 3. HER expression was negative. 4. There are no contraindications to chemotherapy, patients who have received anthracyclines and paclitaxel adjuvant therapy before and have not used capecitabine and/or vinorelbine. 5. Physical condition (KPS) score =70 points; 6. The expected survival time is more than 3 months. 7.The patient (legal representative *) can understand the purpose of treatment, voluntarily accept the treatment plan and agree to follow-up at the later stage, have good compliance and can sign the informed consent form for chemotherapy (including clinical observation tips); 8.The treatment plan should at least include vinorelbine soft capsules.
Exclusion criteria
Exclusion criteria: 1. Patients generally have poor condition and cannot tolerate chemotherapy. 2. The toxicity of previous anti-tumor therapy has not yet recovered to CT CAE (version 4.03) grade 0-1; 3. Positive patients have systemic diseases without stable control, including severe diabetes, hypertension, lung diseases and liver diseases, etc. 4. Is suffering from active infection requiring systematic treatment; 5. Active tuberculosis history, active hepatitis B or hepatitis C patients (HBsAg positive and HBV DNA copy number positive; HBcAb positive) and HIV positive; 6. Patients who are transferred to hospital or give up treatment during treatment; 7. Patients taking other drugs that may affect the effect of chemotherapy during treatment; 8. Pregnant or lactating women patients; Women of childbearing age refuse to accept contraceptive measures; 9. Researchers think that it is not suitable for the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| DCR;OS; | — |
Countries
China
Contacts
Public ContactZhong Wei
Hubei Cancer Hospital
Outcome results
None listed